These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23588952)

  • 1. Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
    Rudek MA; Connolly RM; Hoskins JM; Garrett-Mayer E; Jeter SC; Armstrong DK; Fetting JH; Stearns V; Wright LA; Zhao M; Watkins SP; McLeod HL; Davidson NE; Wolff AC
    Breast Cancer Res Treat; 2013 May; 139(1):135-43. PubMed ID: 23588952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients.
    Villalona-Calero MA; Blum JL; Jones SE; Diab S; Elledge R; Khoury P; Von Hoff D; Kraynak M; Moczygemba J; Kromelis P; Griffin T; Rowinsky EK
    Ann Oncol; 2001 May; 12(5):605-14. PubMed ID: 11432617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
    Roxburgh P; Lumsden GR; Paul J; Harden S; Sweeting L; James A; Crellin A; Morrison R; Evans TR; McDonald AC
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):131-9. PubMed ID: 24819683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
    Schott AF; Rae JM; Griffith KA; Hayes DF; Sterns V; Baker LH
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):129-35. PubMed ID: 16283312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
    Talbot DC; Moiseyenko V; Van Belle S; O'Reilly SM; Alba Conejo E; Ackland S; Eisenberg P; Melnychuk D; Pienkowski T; Burger HU; Laws S; Osterwalder B
    Br J Cancer; 2002 May; 86(9):1367-72. PubMed ID: 11986765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
    Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
    Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
    Partridge AH; Archer L; Kornblith AB; Gralow J; Grenier D; Perez E; Wolff AC; Wang X; Kastrissios H; Berry D; Hudis C; Winer E; Muss H
    J Clin Oncol; 2010 May; 28(14):2418-22. PubMed ID: 20368559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
    Hennessy BT; Gauthier AM; Michaud LB; Hortobagyi G; Valero V
    Ann Oncol; 2005 Aug; 16(8):1289-96. PubMed ID: 15890665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
    Daher Abdi Z; Lavau-Denes S; Prémaud A; Urien S; Sauvage FL; Martin J; Leobon S; Marquet P; Tubiana-Mathieu N; Rousseau A
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1285-93. PubMed ID: 24801171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
    Ambros T; Zeichner SB; Zaravinos J; Montero AJ; Ahn E; Aruna M; Kronish L; Mahtani RL; Vogel CL
    Breast Cancer Res Treat; 2014 Jul; 146(1):7-14. PubMed ID: 24899084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine in elderly patients with metastatic breast cancer.
    De Sanctis R; Quadrini S; Longo F; Lapadula V; Restuccia R; Del Signore E; De Filippis L; Stumbo L; Gori B; Bianco V; Speranza I; Basile ML; Di Seri M
    Tumori; 2012; 98(3):303-7. PubMed ID: 22825504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
    Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW
    Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
    Kusama M; Nomizu T; Aogi K; Yoshimoto M; Horikoshi N; Tabei T; Noguchi S; Miura S; Yoshimura N; Kimura M; Toyama K; Shin E
    Breast Cancer; 2010 Oct; 17(4):233-40. PubMed ID: 19633909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
    Nolè F; Catania C; Sanna G; Imadalou K; Munzone E; Adamoli L; Longerey B; Blanchot G; Goldhirsch A
    Ann Oncol; 2006 Feb; 17(2):322-9. PubMed ID: 16303864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.
    Babacan T; Efe O; Hasirci AS; Demirci F; Buyukhatipoglu H; Balakan O; Sarici F; Kertmen N; Esin E; Akin S; Ates O; Aksoy S; Sever AR; Altundag K
    Tumori; 2015; 101(4):418-23. PubMed ID: 25953439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
    Lokich J
    Cancer Invest; 2004; 22(5):713-7. PubMed ID: 15581052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
    Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.